Published in Medical Letter on the CDC and FDA, December 5th, 2004
The conditions of approval require the standard continued postmarketing surveillance and annual update reports to the FDA and physician users.
"This is an eventful day for people with AAA and their physicians, as well as for the employees and shareholders of Endologix," said Paul McCormick, president and chief executive officer. "Use of ELGs...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA